Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1999 1
2000 1
2003 1
2008 1
2009 1
2010 7
2011 7
2012 11
2013 38
2014 31
2015 36
2016 22
2017 11
2018 9
2019 2
2020 1
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 24809799

165 results
Results by year
Filters applied: . Clear all
Page 1
Sorafenib use in the transplant setting.
Castelli G, Burra P, Giacomin A, Vitale A, Senzolo M, Cillo U, Farinati F. Castelli G, et al. Liver Transpl. 2014 Sep;20(9):1021-8. doi: 10.1002/lt.23911. Epub 2014 Aug 4. Liver Transpl. 2014. PMID: 24809799 Free article. Review.
Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
Jia N, Liou I, Halldorson J, Carithers R, Perkins J, Reyes J, Yeh M, Stohr E, Rao S, Lin EH. Jia N, et al. Anticancer Res. 2013 Jun;33(6):2797-800. Anticancer Res. 2013. PMID: 23749944 Clinical Trial.
Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC, Nowak KW, Fouzas I, Vernadakis S, Kykalos S, Klein CG, Paul A. Sotiropoulos GC, et al. Transplant Proc. 2012 Nov;44(9):2754-6. doi: 10.1016/j.transproceed.2012.09.022. Transplant Proc. 2012. PMID: 23146514
Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C, Airoldi A, Mancuso A, Vangeli M, ViganĂ² R, Cordone G, Gentiluomo M, Belli LS. Zavaglia C, et al. Eur J Gastroenterol Hepatol. 2013 Feb;25(2):180-6. doi: 10.1097/MEG.0b013e328359e550. Eur J Gastroenterol Hepatol. 2013. PMID: 23044808 Review.
Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P, Crocetti L, Pezzati D, Bargellini I, Ghinolfi D, Carrai P, Leonardi G, Della Pina C, Cioni D, Pollina L, Campani D, Bartolozzi C, Lencioni R, Filipponi F. De Simone P, et al. Transplant Proc. 2014 Jan-Feb;46(1):241-4. doi: 10.1016/j.transproceed.2013.10.035. Transplant Proc. 2014. PMID: 24507059
Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review.
Golse N, Radenne S, Rode A, Ducerf C, Mabrut JY, Merle P. Golse N, et al. Exp Clin Transplant. 2018 Apr;16(2):227-236. doi: 10.6002/ect.2015.0299. Epub 2016 May 17. Exp Clin Transplant. 2018. PMID: 27212671 Free article. Review.
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.
Chen K, Man K, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Chen K, et al. Liver Transpl. 2014 Mar;20(3):261-9. doi: 10.1002/lt.23806. Epub 2014 Jan 27. Liver Transpl. 2014. PMID: 24376158 Free article. Review.
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
de'Angelis N, Landi F, Carra MC, Azoulay D. de'Angelis N, et al. World J Gastroenterol. 2015 Oct 21;21(39):11185-98. doi: 10.3748/wjg.v21.i39.11185. World J Gastroenterol. 2015. PMID: 26494973 Free PMC article. Review.
Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
Zheng SZ, Liu DJ, Sun P, Yu GS, Xu YT, Gong W, Liu J. Zheng SZ, et al. World J Gastroenterol. 2014 Nov 21;20(43):16275-81. doi: 10.3748/wjg.v20.i43.16275. World J Gastroenterol. 2014. PMID: 25473183 Free PMC article.
Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Narayanan Menon KV, Estfan B, Romero-Marrero C, Aucejo F. Waghray A, et al. Clin Transplant. 2013 Jul-Aug;27(4):555-61. doi: 10.1111/ctr.12150. Epub 2013 Jun 13. Clin Transplant. 2013. PMID: 23758296
165 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback